Future experiments should assess TGM2 inhibitor delivery strategies in clinically relevant animal models of glioblastoma, along with efficacy experiments as a single agent and in combination with standard therapy and immune checkpoint inhibition. The gene discussed is TGM2; the disease is glioblastoma.